drugset / Trial / NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1
Recruiting
24 enrolled
M.D. Anderson Cancer Center
Cannonball Kids' Cancer Foundation · collabTreovir, Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Timeline
- Start
- 2019-09-12
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G207 | Other / unclassified | — | Other |